Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.

about

Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.

Item

http://www.wikidata.org/entity/Q55632531

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Salvage pembrolizumab added to ...... anaplastic thyroid carcinoma.

@en

Salvage pembrolizumab added to ...... anaplastic thyroid carcinoma.

@nl

type

Item

label

Salvage pembrolizumab added to ...... anaplastic thyroid carcinoma.

@en

Salvage pembrolizumab added to ...... anaplastic thyroid carcinoma.

@nl

prefLabel

Salvage pembrolizumab added to ...... anaplastic thyroid carcinoma.

@en

Salvage pembrolizumab added to ...... anaplastic thyroid carcinoma.

@nl

P1476

Salvage pembrolizumab added to ...... anaplastic thyroid carcinoma.

@en

P2093

Erich M Sturgis

http://www.w3.org/2001/XMLSchema#string

G Brandon Gunn

http://www.w3.org/2001/XMLSchema#string

Heath D Skinner

http://www.w3.org/2001/XMLSchema#string

Horiana Grosu

http://www.w3.org/2001/XMLSchema#string

Maria E Cabanillas

http://www.w3.org/2001/XMLSchema#string

Maria Gule-Monroe

http://www.w3.org/2001/XMLSchema#string

Naifa L Busaidy

http://www.w3.org/2001/XMLSchema#string

Neil Gross

http://www.w3.org/2001/XMLSchema#string

Priyanka C Iyer

http://www.w3.org/2001/XMLSchema#string

Ramona Dadu

http://www.w3.org/2001/XMLSchema#string

P2860

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

COSMIC: exploring the world's knowledge of somatic mutations in human cancer

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.

The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.

The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring.

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.

Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery.

Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer

Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer

P2888

s40425-018-0378-y

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S40425-018-0378-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mark E Zafereo

Mouhammed Amir Habra

Michelle D Williams

P577

2018-07-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1105485481

http://www.w3.org/2001/XMLSchema#string

P698

29996921

http://www.w3.org/2001/XMLSchema#string

P932

6042271

http://www.w3.org/2001/XMLSchema#string